Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib

Bibliography

• Hussain SA, Ferry DR, El-Gazzaz G, Hepatocellular carcinoma. Ann Oncol 2001;12(2):161-72
   PubMedGoogle Scholar
• El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139(10):817-23
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745-50
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S97-103
   PubMed Web of Science ®Google Scholar
• Fan ST, Lo CM, Liu CL, Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229(3):322-30
   PubMedGoogle Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37(2):429-42
   PubMedGoogle Scholar
• Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004;13(12):1555-68
   PubMedGoogle Scholar
• Gish RG, Porta C, Lazar L, Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007;25(21):3069-75
   PubMedGoogle Scholar
• Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009;100(1):19-23
   PubMedGoogle Scholar
• Theise ND, Yao JL, Harada K, Hepatic'stem cell'malignancies in adults: four cases. Histopathology 2003;43(3):263-71
   PubMedGoogle Scholar
• Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31(4):339-46
   PubMed Web of Science ®Google Scholar
• Feitelson MA, Sun B, Satiroglu Tufan NL, Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21(16):2593-604
   PubMedGoogle Scholar
• Pang RW, Joh JW, Johnson PJ, Biology of hepatocellular carcinoma. Ann Surg Oncol 2008;15(4):962-71
   PubMedGoogle Scholar
• Epstein RJ, Leung TW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 2007;13(1):11-7
   PubMedGoogle Scholar
• Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163(3):1101-7
   PubMedGoogle Scholar
• Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242(2):151-67
   PubMedGoogle Scholar
• Lee JS, Heo J, Libbrecht L, A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12(4):410-6
   PubMedGoogle Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
   PubMed Web of Science ®Google Scholar
• Hsu C, Shen YC, Cheng CC, Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 2010;31(1):55-61
   PubMedGoogle Scholar
• Abou-Alfa GK, Amadori D, Santoro A, Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008;26(20 Suppl): abstract 4518
   Google Scholar
• Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48(4):1312-27
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. In: ECCO (European Journal of Cancer Supplements, Barcelona) 2007. p. 259
   Google Scholar
• Yau T, Chan P, Cheung FY, Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. In: Joint ECCO 15 – 34th ESMO Multidisciplinary Congress (European Journal of Cancer Supplements, Berlin) 2009. p. 1-24
   Google Scholar
• Prete SD, Montella L, Caraglia M, Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 2009
   Google Scholar
• Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72(Suppl 1):30-44
   PubMedGoogle Scholar
• Miura H, Miyazaki T, Kuroda M, Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997;27(5):854-61
   PubMed Web of Science ®Google Scholar
• Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 1997;76(6):689-93
   PubMedGoogle Scholar
• Asahara T, Bauters C, Zheng LP, Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995;92(9 Suppl):II365-371
   PubMedGoogle Scholar
• Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006;12(26):4241-5
   PubMedGoogle Scholar
• Chow NH, Hsu PI, Lin XZ, Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1997;28(6):698-703
   PubMedGoogle Scholar
• Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007;26(3-4):443-52
   PubMedGoogle Scholar
• Presta LG, Chen H, O'Connor SJ, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57(20):4593-9
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26(18):2992-8
   PubMed Web of Science ®Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(12):1898-903
   PubMed Web of Science ®Google Scholar
• Thomas MB, Morris JS, Chadha R, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27(6):843-50
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Iwasaki M, Javle M, Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). In: 2009 ASCO Annual Meeting. J Clin Oncol Chicago 2009
   Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
   PubMed Web of Science ®Google Scholar
• Zhu AX, Sahani DV, Duda DG, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27(18):3027-35
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boucher E, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10(8):794-800
   PubMed Web of Science ®Google Scholar
• Koeberle D, Montemurro M, Samaras P, Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): a multicenter phase II trial (SAKK 77/06 and SASL 23). In: ASCO (Orlando, 2009)
   Google Scholar
• Wood JM, Bold G, Buchdunger E, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60(8):2178-89
   PubMedGoogle Scholar
• Liu Y, Poon RT, Li Q, Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005;65(9):3691-9
   PubMed Web of Science ®Google Scholar
• Koch I, Baron A, Roberts S, Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). In: 2005 ASCO Annual Meeting Proceedings. (Journal of Clinical Oncology, Orlando) No 16S (June 11 Supplement), 2005:4134
   Google Scholar
• Yau T, Chan P, Ng KK, Phase I/II Trial of PTK787 /ZK222584 Combined with Intravenous Doxorubicin for Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC): Implication for Anti-angiogenic Approach To HCC. Cancer 2010. (In Press)
   Google Scholar
• Kohne CEB, Lin E, Valle JW, Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. In: ASCO (Chicago, 2007)
   Google Scholar
• Hecht JR, Trarbach T, Jaeger E, Final overall survival results of CONFIRM 1, a randomized, double-blind, placebo-controlled phase III trial inpatients with metastatic adenocarcinoma of the colon or rectum receiving first line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo. Euro J Cancer 2007;5(4 Suppl):3010
   Google Scholar
• Presta M, Dell'Era P, Mitola S, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16(2):159-78
   PubMed Web of Science ®Google Scholar
• Uematsu S, Higashi T, Nouso K, Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20(4):583-8
   PubMedGoogle Scholar
• Raoul JL, Finn RS, Kang YK, An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). In: ASCO (Chicago, 2009)
   Google Scholar
• Yau CC, Chen PJ, Curtis CM, A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. In: ASCO (Chicago, 2009)
   Google Scholar
• Toh H, Chen P, Carr BI, A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. In: ASCO (Chicago, 2009)
   Google Scholar
• Kanai F, Yoshida H, Tateishi R, TSU-68 HCC study group Final result of a phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma. In: ASCO (Chicago, 2008)
   Google Scholar
• Alberts SR, Morlan BW, Kim GP, NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)–Interim review of toxicity. In: GI ASCO (Orlando, 2007)
   Google Scholar
• Ito Y, Takeda T, Sakon M, Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84(10):1377-83
   PubMedGoogle Scholar
• Yeh YC, Tsai JF, Chuang LY, Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 1987;47(3):896-901
   PubMed Web of Science ®Google Scholar
• Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997;3(7):1059-66
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Carr BI, Nalesnik MA. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 1995;58(4):240-5
   PubMedGoogle Scholar
• Zhu AX, Stuart K, Blaszkowsky LS, Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2008;15(12):2733-9
   Google Scholar
• Asnacios A, Fartoux L, Romano O, Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112(12):2733-9
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23(27):6657-63
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K, Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110(5):1059-67
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Giantonio BJ, Levy DE, Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2006;24(18S):4143
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Markowitz J, Prescott N, A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15(18):5895-901
   PubMed Web of Science ®Google Scholar
• Hsu C, Huang CL, Hsu HC, HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 2002;94(2):415-20
   PubMedGoogle Scholar
• Heinze T, Jonas S, Karsten A, Neuhaus P. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res 1999;19(4A):2501-3
   PubMedGoogle Scholar
• Su Q, Liu Y. Expression of c-erbB-2 protein and EGF receptor in hepatitis B, cirrhosis and hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 1995;24(2):93-5
   PubMedGoogle Scholar
• Rusnak DW, Lackey K, Affleck K, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1(2):85-94
   PubMedGoogle Scholar
• Fingar DC, Richardson CJ, Tee AR, mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24(1):200-16
   PubMed Web of Science ®Google Scholar
• Schmitz KJ, Wohlschlaeger J, Lang H, Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008;48(1):83-90
   PubMed Web of Science ®Google Scholar
• Villanueva A, Chiang DY, Newell P, Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135(6):1972-83, 1983 e1971-1911
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276(5309):60-6
   PubMedGoogle Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4(12):915-25
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4(7):505-18
   PubMedGoogle Scholar
• Marotta F, Vangieri B, Cecere A, Gattoni A. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ther 2004;155(5):187-99
   Google Scholar
• Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008;28(2):160-74
   PubMedGoogle Scholar
• Sun S, Lee NP, Poon RT, Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int 2007;27(8):1021-38
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-300
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Letourneau R, Harker G, Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006;24(27):4441-7
   PubMedGoogle Scholar
• Llovet J, Pena C, Shan M, Biomarkers predicting outcome of patients with hepatocellular carcinoma: results from the randomised phase III SHARP trial. In: AASLD 59th annual meeting 2008
   Google Scholar
• Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009;29(1):10-7
   PubMedGoogle Scholar